MG-K10 injection for moderate-to-severe eczema in teenagers
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests an injectable medication called MG-K10 to treat moderate-to-severe atopic dermatitis (eczema) in teenagers aged 12–17. The medication may help reduce itching and skin inflammation if topical creams haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with atopic dermatitis (eczema) for at least 6 months
- Moderate-to-severe eczema affecting at least 10% of body and scoring ≥16 on severity scale
- Intense itching (rated ≥4 out of 10 on average per week)
- Topical treatments (creams/ointments) either haven't worked or aren't safe for you
- No recent or planned biologic drugs, immunosuppressants, or other specialty eczema treatments
- Able to receive needle injections; no bleeding disorders or anticoagulant use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
This study tests a new drug called MG-K10 for people with atopic dermatitis (also known as eczema) that did not get better with creams or ointments. It aims to see if the drug can help control the condition safely.
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
Hear when a new Dermatitis, Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.